Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart
I'm PortAI, I can summarize articles.
Eledon Pharmaceuticals is conducting a Phase 2 clinical study, ‘AT-1501-K209: BESTOW-EXTENSION’, to evaluate the long-term safety and efficacy of Tegoprubart in kidney transplant recipients. The study compares Tegoprubart with Tacrolimus, focusing on preventing transplant rejection. It began on November 6, 2023, and aims to provide insights that could influence investor confidence and stock performance. The study is ongoing, with updates available on the ClinicalTrials portal.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments